Semathera

About:

SemaThera is a spin-off company from AmorChem Venture Fund 1

Twitter/X: Sema_Thera

Top Investors: Amorchem, Senju Pharmaceutical

Description:

SemaThera is a spin-off company from AmorChem Venture Fund 1, focusing on SEMA 3A protein inhibitor in the treatment of ocular diseases, such as diabetic macular edema. This technology emerges from the laboratory of Dr Mike Sapieha, Hôpital Maisonneuve-Rosement (Montreal, Canada).

Total Funding Amount:

$3.6M

Headquarters Location:

Westmount, Quebec, Canada

Founded Date:

2016-01-01

Contact Email:

info(AT)semathera.com

Founders:

Przemyslaw Sapieha

Number of Employees:

1-10

Last Funding Date:

2018-03-26

IPO Status:

Private

Industries: